Showing results (401-410 of 491) with videos related to

Sort By:
Pageof 50
Blood Advances|February 19, 2021
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registryJean-Pierre Bassand, Saverio Virdone, Marc Badoz, et al.
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
BMJ (Clinical Research Ed.)|January 23, 2015
High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort studyAnoop S V Shah, Megan Griffiths, Kuan Ken Lee, et al.
Scientific Reports|April 12, 2020
Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity MeasurementsKristian C Becker, Lydia Coulter Kwee, Megan L Neely, et al.
Circulation|March 23, 2005
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot TrialShamir R Mehta, Philippe Gabriel Steg, Christopher B Granger, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
JACC. Cardiovascular Interventions|March 19, 2018
Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI TrialMathieu Kerneis, C Michael Gibson, Gerald Chi, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|April 23, 2021
GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillationKeith A A Fox, Saverio Virdone, Karen S Pieper, et al.
Circulation|October 29, 2008
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trialsShamir R Mehta, William E Boden, John W Eikelboom, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 50